Please use this identifier to cite or link to this item:
Title: The Weakening of Pharmaceutical Method Patents: The Federal Circuit Addresses the ‘FDA Conundrum’
Authors: Higgins, Brian Wm
Lessler, Jay P
Keywords: Hatch-Waxman;safe harbor;Label;Prescribing information;FDA;Injunction;ANDA;Submission;Bioequivalence;Sameness;Federal Circuit;Federal Circuit
Issue Date: Mar-2014
Publisher: NISCAIR-CSIR, India
Abstract: The US Food and Drug Administration (FDA) has strict requirements for generic drugs. These requirements may prevent a generic manufacturer from altering a drug product to unequivocally avoid patent infringement, and may also require a generic manufacturer to use a patented method for quality control purposes. These situations are called the ‘FDA conundrum.’ While Congress and the FDA desire to have generic drugs enter the market as soon as possible, the requirements FDA imposes raise issues of patent infringement that often take years to resolve. The Federal Circuit addressed these issues in the year 2012, in three separate cases: Momenta v Amphastar, AstraZeneca v Apotex, and Bayer Schering Pharma AG v Lupin.
Page(s): 89-96
ISSN: 0975-1076 (Online); 0971-7544 (Print)
Appears in Collections:JIPR Vol.19(2) [March 2014]

Files in This Item:
File Description SizeFormat 
JIPR 19(2) 89-96.pdf76.6 kBAdobe PDFView/Open

Items in NOPR are protected by copyright, with all rights reserved, unless otherwise indicated.